Role of Haloperidol in Palliative Medicine: An Update

Eric Prommer

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalAmerican Journal of Hospice and Palliative Medicine
Issue number4
StatePublished - Jun 2012


  • QT interval
  • delirium
  • dopamine
  • dosing
  • haloperidol
  • nausea

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Role of Haloperidol in Palliative Medicine: An Update'. Together they form a unique fingerprint.

Cite this